--> TEVA +11% in Tel Aviv
Teva Pharma beats by $0.14, beats on revs; raises FY15 EPS, in-line
Reports Q2 (Jun) earnings of $1.43 per share, $0.14 better than the Capital IQ Consensus Estimate of $1.29; revenues fell 1.5% year/year to $4.97 bln vs the $4.9 bln consensus.
- Co raises guidance for FY15, sees EPS of $5.15-5.40 vs. $5.21 Capital IQ Consensus Estimate.up previously provided EPS range of $5.05 to $5.35, up previously provided EPS range of $5.05 to $5.35.